Celcuity, Inc. (CELC)
91.80
-0.47
(-0.51%)
USD |
NASDAQ |
Aug 26, 09:49
Celcuity Total Liabilities (Quarterly) : 841.00M for June 30, 2026
Total Liabilities (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Total Liabilities (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | 841.00M |
| March 31, 2026 | 356.64M |
| December 31, 2025 | 366.00M |
| September 30, 2025 | 359.04M |
| June 30, 2025 | 139.22M |
| March 31, 2025 | 131.46M |
| December 31, 2024 | 129.50M |
| September 30, 2024 | 123.33M |
| June 30, 2024 | 115.86M |
| March 31, 2024 | 54.44M |
| December 31, 2023 | 51.45M |
| September 30, 2023 | 49.49M |
| June 30, 2023 | 43.38M |
| March 31, 2023 | 41.65M |
| December 31, 2022 | 41.93M |
| September 30, 2022 | 21.77M |
| June 30, 2022 | 19.16M |
| March 31, 2022 | 18.39M |
| December 31, 2021 | 17.20M |
| Date | Value |
|---|---|
| September 30, 2021 | 17.36M |
| June 30, 2021 | 15.77M |
| March 31, 2021 | 1.192M |
| December 31, 2020 | 1.254M |
| September 30, 2020 | 1.152M |
| June 30, 2020 | 0.8401M |
| March 31, 2020 | 0.8776M |
| December 31, 2019 | 0.9832M |
| September 30, 2019 | 1.030M |
| June 30, 2019 | 1.049M |
| March 31, 2019 | 1.077M |
| December 31, 2018 | 0.6822M |
| September 30, 2018 | 0.9819M |
| June 30, 2018 | 0.9861M |
| March 31, 2018 | 0.783M |
| December 31, 2017 | 0.5781M |
| September 30, 2017 | 0.3364M |
| June 30, 2017 | 7.352M |
| March 31, 2017 | 0.3696M |
Total Liabilities Definition
Liabilities are a main portion of the balance sheet of a company that measure outstanding payables/obligations. A few examples of liabilties of a company include accounts payable, current debt, and capital lease obligations. From an accounting perspective, the balance sheet equation is Liabilties = Assets - Shareholder's Equity.
Total Liabilities (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Total Liabilities (Quarterly) Benchmarks
| Cogent Biosciences, Inc. | 302.16M |
| Replimune Group, Inc. | 146.80M |
| Erasca, Inc. | 73.18M |
| Apogee Therapeutics, Inc. | 141.21M |
| Arrowhead Pharmaceuticals, Inc. | 1.646B |
Total Liabilities (Quarterly) Related Metrics
| Total Assets (Quarterly) | 828.22M |
| Shareholders Equity (Quarterly) | -12.78M |
| Debt to Equity Ratio | -59.02 |
| Current Ratio | 8.931 |
| Net Debt Paydown Yield | -2.56% |